Neuromodulation by SCS for poststroke pain
Project/Area Number |
24592176
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Cerebral neurosurgery
|
Research Institution | Nihon University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
FUKAYA Chikashi 日本大学, 医学部, 准教授 (50287637)
OSHIMA Hideki 日本大学, 医学部, 准教授 (20328735)
KOBAYASHI Kazutaka 日本大学, 医学部, 准教授 (20366579)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 脊髄刺激 / 脳卒中後疼痛 / ケタミン / ドラッグチャレンジテト / spinal cord stimulation / poststroke pain / motor weakness / ketamine / neuromodulation |
Outline of Final Research Achievements |
We have examined whether the pharmacological evaluation of central poststroke pain (CPSP) is useful to select the candidate of SCS therapy, and examined about the analgesic effects of dual-lead SCS in CPSP patients. Changes in visual analog scale (VAS) score for pain following pharmacological evaluation using morphine, thiopental, and ketamine were compared with the long-term follow up results of dual-lead SCS. Effective pain reduction by dual-lead SCS in CPSP patients were obtained mainly in ketapine-sensitive cases. Among 27 ketamin-sensitive patients, chronic implantation was applied in 21 of 27 (77.7%) patients. The dual-lead SCS showed long-lasting pain reduction in 15 of 21 (71.4%) CPSP patients. We conclude that pharmacological evaluation and dual-lead SCS are very important for the treatment of CPSP patients, and that ketamine-sensitive CPSP patients are good candidate for dual-lead SCS therapy.
|
Report
(4 results)
Research Products
(31 results)